David Loew - Ipsen SA CEO MD
| I7G Stock | EUR 107.30 0.20 0.19% |
Insider
David Loew is CEO MD of Ipsen SA
| Age | 56 |
| Phone | 33 1 58 33 50 00 |
| Web | https://www.ipsen.com |
Ipsen SA Management Efficiency
The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christophe Weber | Takeda Pharmaceutical | 57 | |
| Armin MD | Swedish Orphan Biovitrum | 65 | |
| Seigo Izumo | Takeda Pharmaceutical | N/A | |
| Tatsuyuki Yasuno | Eisai Co | 55 | |
| MBA MBA | Dr Reddys Laboratories | 54 | |
| Christopher OReilly | Takeda Pharmaceutical | N/A | |
| Robert Polzer | Zoetis Inc | 54 | |
| Sanjay BTech | Dr Reddys Laboratories | 55 | |
| Gunupati BE | Dr Reddys Laboratories | 63 | |
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Steven Esq | Catalent | 60 | |
| Amir Weiss | Teva Pharmaceutical Industries | 46 | |
| MS BTech | Dr Reddys Laboratories | 56 | |
| Eli Shani | Teva Pharmaceutical Industries | N/A | |
| Karen Santiago | Catalent | 52 | |
| Christine Wesstrom | Swedish Orphan Biovitrum | 48 | |
| Kazuhiro Hatanaka | Shionogi Co | N/A | |
| Kevin Mannix | Teva Pharmaceutical Industries | N/A | |
| Gabriele Ricci | Takeda Pharmaceutical | 45 | |
| Anders MD | Swedish Orphan Biovitrum | 67 | |
| Nadeem Sarwar | Eisai Co | N/A | |
Management Performance
Ipsen SA Leadership Team
Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aidan Murphy, Ex Operations | ||
| David Loew, CEO MD | ||
| Gwenan White, Ex Affairs | ||
| Craig Marks, VicePres Relations | ||
| Francois Garnier, Gen Affairs | ||
| Yan MD, VP Area | ||
| Aymeric Chatelier, Ex CFO | ||
| Regis Mulot, Ex Officer | ||
| Stephan Gagne, Head Office | ||
| Dominique Bery, Head Baltics |
Ipsen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 8.46 B | |||
| Shares Outstanding | 82.63 M | |||
| Shares Owned By Insiders | 57.12 % | |||
| Shares Owned By Institutions | 20.19 % | |||
| Price To Earning | 20.55 X | |||
| Price To Book | 2.88 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ipsen Stock
Ipsen SA financial ratios help investors to determine whether Ipsen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ipsen with respect to the benefits of owning Ipsen SA security.